FDA Approval Insights: Durvalumab/Chemotherapy in dMMR Advanced Endometrial Cancer

Season 11 Episode 3  ·  Aug 15, 2024, 06:20 PM

Headliner
Share
Subscribe

Dr Westin discusses the FDA approval of durvalumab plus chemotherapy for patients with dMMR advanced or recurrent endometrial cancer.

Share
Subscribe
Next
Garcia-Manero on MDS Treatment Updates With Luspatercept and Beyond
Top episodes
DeNunzio Describes the Advantages of Proton Beam Therapy in Oncology
by OncLive® On Air
FDA Approval Insights: Amivantamab and Mobocertinib in EGFR Exon 20 Insertion+ NSCLC
by OncLive® On Air
Milhem Talks Mechanism of Action, Delivery Methodology, and Ongoing Trials With RP1
by OncLive® On Air